Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treat and Train - A Post-Marketing-Observational Study (PMOS) to Determine the Effectiveness of Combined Adalimumab Treatment and Active Supervised Training in Patients With Axial Spondyloarthritis

Trial Profile

Treat and Train - A Post-Marketing-Observational Study (PMOS) to Determine the Effectiveness of Combined Adalimumab Treatment and Active Supervised Training in Patients With Axial Spondyloarthritis

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 07 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Ankylosing spondylitis; Non-radiographic axial spondyloarthritis; Spondylarthritis
  • Focus Therapeutic Use
  • Acronyms Treat & Train
  • Sponsors AbbVie
  • Most Recent Events

    • 12 Sep 2018 Status changed from recruiting to discontinued due to low or no enrollment.
    • 29 Mar 2018 Status changed from not yet recruiting to recruiting.
    • 16 Feb 2018 Planned number of patients changed from 600 to 510.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top